Corporate Banner
Satellite Banner
Proteomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Genalyte Launches Multiplexed Test Streamlining Immunogenicity Testing

Published: Tuesday, April 09, 2013
Last Updated: Tuesday, April 09, 2013
Bookmark and Share
Automated multi-tier ADA test combines screening, confirmatory and isotyping steps in a single assay.

Genalyte, Inc. has announced the launch of its MT-ADA™ anti-drug antibody (ADA) immunogenicity assay designed to run on the Maverick™ Detection System.

This test combines screening for the presence of ADAs and the characterization of each detected ADA with a full isotype profile.

With minimal required sample preparation and its combination of detection and characterization in a single assay, the MT-ADA assay streamlines ADA testing for both mouse and human samples, providing real-time detection without the use of dyes, fluorescent probes or radioactive labels.

Immunogenicity is triggered when the body generates an unwanted immune response to a drug. The resulting anti-drug antibodies can reduce the efficacy of the drug and cause a variety of harmful effects.

As a result, clinical testing of drug candidates to identify potential immunogenicity issues arising from anti-drug antibodies has become common. The new MT-ADA assay is designed for rapid, efficient and accurate ADA testing.

“Immunogenicity testing currently requires multiple steps and significant hands-on effort,” said Martin Gleeson, PhD, Chief Scientific Officer of Genalyte.

Gleeson continued, “MT-ADA simplifies and speeds up this process, combining the screening, confirmatory and isotyping steps in an automated assay that is efficient to develop and uses standard sample preparation methods. Early feedback from drug developers has been positive and we are pleased to now make the MT-ADA assay widely available to Maverick System users.”

The MT-ADA chip provides simultaneous ADA detection and confirmation for eight antibody classes/isotypes. The Maverick System’s multiplex capacity and kinetic measurement capability streamline assay development by enabling simultaneous assessment of assay sensitivity and free drug tolerance for total ADAs and for each antibody class.

The MT-ADA assay is compatible with commonly accepted sample preparation methodologies.

Genalyte’s Maverick Detection System uses a silicon chip containing arrays of photonic ring sensors that simultaneously analyze multiple antibodies and other proteins from a single small sample.

The one-step workflow of the Maverick Multiplex System can deliver accurate results in as little as 15 minutes from small volume samples of many types. The Maverick platform has a large dynamic range and excellent sensitivity with outstanding reproducibility.

Current commercially available tests for the Maverick Detection System include MT-ADA, ENA 4, ENA 6 and ANA 14 assay kits . Assay kits for SLE, Sjogren’s syndrome and type I diabetes research are available under Genalyte’s Technology Access Program.

Additionally, Genalyte offers researchers a Custom Spotting Service that loads proteins supplied by customers, such as antibodies, peptides, biomarkers, cytokines and antigens, on to standard-format Genalyte chips that are ready to be run on the Maverick System.

Learn more the Maverick Detection System and its multiplexed assays at the following upcoming conferences.

• PEGS 2013: The Essential Protein Engineering Summit, Boston, MA, April 29-May 3, 2013, Booth 115
• American Assoc. of Pharmaceutical Scientists (AAPS) National Biotechnology Conference, San Diego, CA, May 20-21, 2013, Booth 704
• Next Generation Protein Therapeutics Summit, San Diego, CA, June 25-27, 2013, Booth 6


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
Computational Model Finds New Protein-Protein Interactions
Researchers at University of Pittsburgh have discovered 500 new protein-protein interactions (PPIs) associated with genes linked to schizophrenia.
New Insights into Gene Regulation
Researchers have solved the three-dimensional structure of a gene repression complex that is known to play a role in cancer.
Controlling RNA in Living Cells
Modular, programmable proteins can be used to track or manipulate gene expression.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Potential Target for Revolutionary Antibiotics
An international team of including the Lomonosov Moscow State University researchers discovered which enzyme enables Escherichia coli bacterium (E. coli) to breathe.
DNA Barcodes Gone Wild
A team of researchers at University of Toronto’s Donnelly Centre and Sinai Health System’s Lunenfeld-Tanenbaum Research Institute (LTRI) has developed a new technology that can stitch together DNA barcodes inside a cell to simultaneously search amongst millions of protein pairs for protein interactions.
Biomarkers for Profiling Prostate Cancer Patients
Exiqon A/S has announced the publication of validation of prognostic microRNA biomarkers for the aggressiveness of prostate cancer in independent cohorts.
Grant to Fund Million Peaks Project
The European Research Council (ERC) has awarded a prestigious Advanced Grant to Prof. Peter Schoenmakers, Prof. Albert Polman and Prof. Huib Bakker, all three of whom work at the University of Amsterdam (UvA).
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!